Thesan series B garners $49M for skin therapies; keeps mum on pipeline
By Randy Osborne
Monday, February 24, 2014
Thesan Pharmaceuticals Inc. followed up last fall’s $16 million series A financing with $49 million in series B money to support research in acne and atopic dermatitis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.